Back to Journals » Neuropsychiatric Disease and Treatment » Volume 10

New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder

Authors Katona C, Katona C

Received 29 October 2013

Accepted for publication 20 November 2013

Published 19 February 2014 Volume 2014:10 Pages 349—354

DOI https://doi.org/10.2147/NDT.S39544

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Cornelius L Katona,1 Cara P Katona2

1Division of Psychiatry, University College London, 2North Central London Psychiatry Training Programme, London, UK

Abstract: Vortioxetine is a novel antidepressant with effects on multiple 5-HT receptors and on the serotonin transporter. This paper reviews preclinical and clinical evidence regarding its mechanism of action, its tolerability, and its efficacy in treating major depression. Clinical studies indicate that vortioxetine is effective in the treatment of major depression, though there is no suggestion of superiority over active comparators. There may be a clinically meaningful advantage in terms of tolerability.

Keywords: vortioxetine, major depression, review

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]